Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.86 |
| ▸ | HPGD | P15428 | 3/20 | 0.86 |
| ▸ | TSHR | P16473 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.62 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.52 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386976 | 1.00 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL4057588 | 1.00 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL3695372 | 1.00 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL1826063 | 1.00 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL3703489 | 0.97 | ALDH1A1 (0.81) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL12714626 | 0.95 | HPGD (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL3706273 | 0.95 | HPGD (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL1309352 | 0.95 | ALDH1A1 (0.86) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL19612780 | 0.92 | HPGD (1.00) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 | |
| SCHEMBL10559542 | 0.92 | ALDH1A1 (1.00) | ALDH1A1HPGDTSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-8153625-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | claimed |
| US-7759336-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | claimed |
| EP-0502119-B1 | LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES | SCIOS NOVA INC (US) | 1996-01-31 | — | — | EP | claimed |
| US-5221535-A | Sustained release formulations of insect repellent | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| EP-0502119-A1 | LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES. | NOVA PHARM CORP (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007171-A1 | LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| CN-114751858-B | Quinolinyl-containing tranexamic acid derivative and preparation and application thereof | 沈阳药科大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230151151-A1 | NOVEL CO-POLYAMIDES | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| EP-0502119-A1 | LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES. | NOVA PHARM CORP (US) | 1992-09-09 | — | — | EP | disclosed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | disclosed |
| CN-1054071-A | Oral active renin inhibitors | PFIZER (US) | 1991-08-28 | — | — | CN | disclosed |
| WO-1991007171-A1 | LIPOSPHERES FOR CONTROLLED DELIVERY OF SUBSTANCES | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-05-30 | — | — | WO | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
| CN-87108011-A | New compounds with pharmacological activity, preparation method and related components thereof | ORION YHTYMAE OY (FI) | 1988-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885HPGD 1030/4885TSHR 4155/4885 |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | ALDH1A1 265/4885HPGD 105/4885TSHR 3065/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885HPGD 1030/4885TSHR 4155/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | ALDH1A1 382/4885HPGD 836/4885TSHR 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.